On March 25, 2026, during the company’s 2025 earnings presentation, Boehringer Ingelheim Chairman Shashank Deshpande touted robust financial results but leveled sharp criticism at the European regulatory landscape, warning of a decline in regional competitiveness.
Financial Performance and US Success Stories:
-
Strong Growth: The group reported 2025 sales of 27.8 billion euros (approx. $31.4 billion), a 7% currency-adjusted increase. The Human Pharma division was led by the blockbuster diabetes and heart failure medicine Jardiance, which generated 8.8 billion euros.
-
Momentum for New Launches: New products Jascayd (for idiopathic pulmonary fibrosis) and Hernexeos (for lung cancer) are seeing “very strong uptake” in the U.S. Jascayd’s launch performance has notably outpaced the historical trajectory of the company’s previous blockbuster, Ofev.
-
Regulatory Disparity: Deshpande highlighted a stark contrast in efficiency, noting the FDA took only 44 business days to grant a label expansion for Hernexeos, whereas equivalent processes in Europe typically languish for six to nine months.
Concerns Over Europe’s Competitiveness:
-
Losing ‘Pharmacy of the World’ Status: The Chairman expressed deep concern that Europe is falling further behind the U.S. and China across all metrics, including clinical trials, new drug approvals, and biotech deal-making.
-
The Burden of Red Tape: Deshpande argued that increasing regulation and bureaucratic hurdles are stifling innovation, causing patients in Boehringer’s home region to wait significantly longer for life-saving treatments.
This strategic outlook underscores a harsh reality: multinational pharmaceutical giants are increasingly prioritizing jurisdictions with faster regulatory frameworks to bring cutting-edge biomedical innovations to market.
Source: https://www.fiercepharma.com/pharma/uptake-boehringers-jascayd-trending-above-ofev-decade-ago